BOARD ADVISORY SERVICES AGREEMENTBoard Advisory Services Agreement • March 17th, 2017 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS BOARD ADVISORY SERVICES AGREEMENT (this “Agreement”) is made as of January 1, 2017, by and between Checkpoint Therapeutics, Inc., a Delaware corporation (the “Company”), and Caribe BioAdvisors, LLC, a Puerto Rico limited liability company (the “Advisor” and individually a “Party” or collectively the “Parties”).
FIRST AMENDMENT TO LICENSE AGREEMENTLicense Agreement • March 17th, 2017 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment to License Agreement (the “Amendment”) is effective as of February 21, 2017 and amends that certain License Agreement, dated March 17, 2015, (the “Agreement”) by and between NeuPharma, Inc. (“Licensor”) and Checkpoint Therapeutics, Inc. (“Checkpoint”). Licensor and Checkpoint are each referred to individually as a “Party” and together as the “Parties.”
EXTENSION OF OPTION AGREEMENTExtension of Option Agreement • March 17th, 2017 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations • New York
As discussed, we would like to extend the Option Period in the Option Agreement dated March 17, 2015 (the “Option Agreement”) between TG Therapeutics, Inc. and Fortress Biotech, Inc. (“Fortress”), as previously extended on September 11, 2015, December 15, 2015, January 11, 2016 and July 8, 2016.
FIRST AMENDMENT TO SUBLICENSE AGREEMENTSublicense Agreement • March 17th, 2017 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS FIRST AMENDMENT TO SUBLICENSE AGREEMENT (this “Amendment”) is made as of December 13, 2016 (the “Effective Date”) between Checkpoint Therapeutics, Inc, a Delaware corporation with its place of business at 2 Gansevoort Street, 9th Floor, New York, New York 10014 (“Checkpoint”), and TG Therapeutics, Inc, a Delaware corporation with its place of business at 2 Gansevoort Street, 9th Floor, New York, New York 10014 (“TGTX”).
Amendment 2 to Exclusive License Agreement between Checkpoint Therapeutics, Inc. and Dana-Farber Cancer Institute, Inc.Checkpoint Therapeutics, Inc. • March 17th, 2017 • Pharmaceutical preparations
This second amendment (“Amendment 2”), made effective as of April 12, 2016 (“Amendment 2 Effective Date”), is between the Dana-Farber Cancer Institute, Inc., a Massachusetts non-profit organization having offices at 450 Brookline Avenue, Boston, MA 02215 (“DFCI”), and Checkpoint Therapeutics, Inc., a Delaware corporation with offices at 3 Columbus Circle, New York, NY 10019 (“CTI”), collectively the “Parties” with reference to the following:
SECOND AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 17th, 2017 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations • New York
Second Amendment (this “Amendment”) dated as of December 15, 2016 to the Executive Employment Agreement (the “Agreement”) dated October 13, 2015, as amended, by and between Checkpoint Therapeutics, Inc. (the “Company” or “Checkpoint”) and James F. Oliviero III (“Oliviero”). All capitalized terms not otherwise defined herein shall have the meanings given to them in the Agreement.
FIRST AMENDMENT TO LICENSE AGREEMENTLicense Agreement • March 17th, 2017 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS FIRST AMENDMENT TO LICENSE AGREEMENT (this “Amendment”) is made as of December 13, 2016 (the “Effective Date”) between Jubilant Biosys Limited, a company organized under the laws of India, having its principal place of business at No. 96, Industrial Suburb, 2nd Stage, Yeshwanthpur, Bangalore – 560022, India (“Licensor”), and Checkpoint Therapeutics, Inc, a Delaware corporation with its place of business at 2 Gansevoort Street, 9th Floor, New York, New York 10014 (“Checkpoint”).
Amendment 3 to Exclusive License Agreement between Checkpoint Therapeutics, Inc. and Dana-Farber Cancer Institute, Inc.License Agreement • March 17th, 2017 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations
This third amendment (“Amendment 3”), made effective as of October 24, 2016 (“Amendment 3 Effective Date”), is between the Dana-Farber Cancer Institute, Inc., a Massachusetts non-profit organization having offices at 450 Brookline Avenue, Boston, MA 02215 (“DFCI”), and Checkpoint Therapeutics, Inc., a Delaware corporation with offices at 2 Gansevoort Street | 9th Floor, New York NY 10014 (“CTI”), collectively the “Parties” with reference to the following:
